Gene therapy slows progression of fatal neurodegenerative disease in children

Gene therapy to replace the faulty CLN2 gene, which causes a neurodegenerative disease that is fatal by age 8-12 years, was able to slow significantly the rate of neurologic decline in treated children, according to a paper published online ahead of print in the May 2008 issue (Vol. 19 No. 5) of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc.

Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is an autosomal recessive genetic disorder that causes degeneration of the central nervous system. It is a form of Batten disease, a group of lysosomal storage disease in which a lipofuscin-like material is not broken down and accumulates in neurons, causing cognitive impairment, visual failure, seizures, and progressive deterioration of motor function.

Ronald Crystal and colleagues from Weill Cornell Medical College (New York, NY), describe a study conducted in 10 children with LINCL who received gene therapy to replace the defective CLN2 gene via administration of human CLN2 carried in an adeno-associated virus (AAV).

In the paper entitled “Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis with CNS Administration of a Serotype 2 Adeno-associated virus expressing the CLN2 cDNA,” the authors report that over an 18-month period, assessment using a neurologic rating scale demonstrated significant slowing of disease progression in the treated, compared to the untreated children. On the basis of these findings, the authors proposed that additional studies to assess the safety and efficacy of AAV-mediated gene therapy for LINCL be pursued.

Although the treatment was associated with some serious adverse events in some patients, these were not unequivocally attributable to the gene therapy vector.

“This clinical trial is an important step toward the development of treatments for this group of underserved inherited neurodegenerative disorders,” says James M. Wilson, MD, PhD, Editor-in-Chief and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania School of Medicine, in Philadelphia.

The paper is available free online at http://www.liebertpub.com/hum .

Source: Mary Ann Liebert, Inc./Genetic Engineering News

Related stories:

Clue to genetic cause of fatal birth defect
A novel enzyme may play a major role in anencephaly, offering hope for a genetic test or even therapy for the rare fatal birth defect in which the brain fails to develop, according to a study from researchers at the University of Illinois at Chicago College of Medicine.
Keeping herpes infection in check: researchers describe immune system strategies
Herpes simplex virus type I can cause bouts of cold sores, blindness and potentially lethal encephalitis when it reawakens from a quiescent state in the nerve cells it infects.
RNA molecules boost vaccine effectiveness
(PhysOrg.com) -- A novel delivery system that could lead to more efficient and more disease-specific vaccines against infectious diseases has been developed by biomedical engineers at The University of Texas at Austin.
New research may help to design better gene therapy vectors
(PhysOrg.com) -- Research published by scientists from the University of Reading may offer an insight into ways of making safer and more specific gene therapy vectors. The research, published in the journal Nature Structural and Molecular Biology, describes the structure of the viral fusion protein gp64, which is involved in the mechanism which viruses use to invade host cells. In the past, Bacloviruses have been suggested as possible gene therapy vectors due to the way in which they enter host cells, but there has been little evidence which explain these properties up to now.
First glimpse of a key DNA repair protein at work
Repairing breaks in the two strands of the DNA double helix is critical for avoiding cancer. In humans and other organisms, a molecular machine called the MRN complex is responsible for finding and signaling double-strand breaks (DSBs), then launching the error-free method of DNA repair called homologous recombination.
What HIV needs: Identification of human factors may yield novel therapeutic targets for HIV
The Salk Institute for Biological Studies and Burnham Institute for Medical Research today announced 295 host cell factors that are involved in human immunodeficiency virus (HIV) infection. The study, published in the Oct. 3 issue of Cell, could lead to the development of a new class of HIV therapeutics aimed at disrupting the human-HIV interactions that lead to viral infection.
Researchers create first model for retina receptors
A team of scientists at the University of Oklahoma Health Sciences Center has created the first genetic research model for a microscopic part of the eye that when missing causes blindness. The research appears in a recent issue of the Journal of Biological Chemistry.
Researchers identify mechanism used by gene to promote metastasis in human cancer cells
Virginia Commonwealth University Institute of Molecular Medicine and VCU Massey Cancer Center researchers have discovered how a gene, melanoma differentiation associated gene-9/syntenin (mda-9/syntenin), interacts with an important signaling protein to promote metastasis in human melanoma cells, a discovery that could one day lead to the development of the next generation of anti-metastatic drugs for melanoma and other cancers.

News discussion:

Medicine & Health news